Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.
about
Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Matrix metalloproteinase 9 is ...... ultifocal leukoencephalopathy.
@en
Matrix metalloproteinase 9 is ...... ultifocal leukoencephalopathy.
@nl
type
label
Matrix metalloproteinase 9 is ...... ultifocal leukoencephalopathy.
@en
Matrix metalloproteinase 9 is ...... ultifocal leukoencephalopathy.
@nl
prefLabel
Matrix metalloproteinase 9 is ...... ultifocal leukoencephalopathy.
@en
Matrix metalloproteinase 9 is ...... ultifocal leukoencephalopathy.
@nl
P2093
P2860
P50
P356
P1433
P1476
Matrix metalloproteinase 9 is ...... multifocal leukoencephalopathy
@en
P2093
Alex Sanchez
Aurélie Ruet
Ayman Tourbah
Berta Miró
Biomarkers and Response to Nat ...... ose En Plaques (SFSEP) Network
Béatrice Pignolet
Caroline Papeix
David Brassat
Jean Pelletier
Juan Carlos Triviño
P2860
P304
P356
10.1002/ANA.24987
P50
P577
2017-07-22T00:00:00Z